Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Omega-3 showdown: which DHA type reaches the brain best?

NCT ID NCT02168738

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests three different forms of DHA (an omega-3 fat) to see which one gets into the body and brain most effectively. Four healthy men aged 60–70 took a single dose of each form, with a four-month break in between. Researchers measured DHA levels in blood cells and plasma six hours after each dose to compare how well the body absorbs each type.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DHA (docosahexaenoic acid) in three forms: triglyceride, phosphatidylcholine, and acetylated lysophosphatidylcholine
What this could lead to
If successful, this could reveal which form of DHA is best absorbed and delivered to the brain, potentially guiding future supplements or treatments for brain health.
What could go wrong
This is a very small, early-stage study in just 4 healthy men, so results may not apply to the general population. It measures short-term blood levels, not actual brain health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

4 people

The number who actually took part.

Start date

Mar 2014

Finished

Apr 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 70 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy male * Aged of 60 to 70 years * Body Mass Index of 20 to 30 kg/m2 * Glycaemic and lipid parameters normal Exclusion Criteria: * Smokers more than ten cigarettes/day * Medical history of personal or family dyslipidemia * Medication that could interfere with lipid metabolism

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy subject are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy subject

Contacts and locations

Locations

  • Centre de Recherche en Nutrition Humaine Rhône-Alpes, 165 chemin du Grand Revoyet,

    Pierre-Bénite, 69310, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.